KR20240116529A - 알츠하이머병 치료에 사용하기 위한 alz-801 - Google Patents

알츠하이머병 치료에 사용하기 위한 alz-801 Download PDF

Info

Publication number
KR20240116529A
KR20240116529A KR1020247022383A KR20247022383A KR20240116529A KR 20240116529 A KR20240116529 A KR 20240116529A KR 1020247022383 A KR1020247022383 A KR 1020247022383A KR 20247022383 A KR20247022383 A KR 20247022383A KR 20240116529 A KR20240116529 A KR 20240116529A
Authority
KR
South Korea
Prior art keywords
alz
day
subject
dose
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022383A
Other languages
English (en)
Korean (ko)
Inventor
수잔 아부샤크라
닐 윌리엄 플란즈라이취
존 헤이
마틴 톨라르
Original Assignee
알제온, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알제온, 인크. filed Critical 알제온, 인크.
Publication of KR20240116529A publication Critical patent/KR20240116529A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020247022383A 2021-12-09 2022-12-09 알츠하이머병 치료에 사용하기 위한 alz-801 Pending KR20240116529A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287552P 2021-12-09 2021-12-09
US63/287,552 2021-12-09
PCT/US2022/052331 WO2023107658A1 (en) 2021-12-09 2022-12-09 Alz-801 for use in treating alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20240116529A true KR20240116529A (ko) 2024-07-29

Family

ID=85157530

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022383A Pending KR20240116529A (ko) 2021-12-09 2022-12-09 알츠하이머병 치료에 사용하기 위한 alz-801

Country Status (10)

Country Link
US (1) US20250041248A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444286A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542844A (cg-RX-API-DMAC7.html)
KR (1) KR20240116529A (cg-RX-API-DMAC7.html)
CN (1) CN118678950A (cg-RX-API-DMAC7.html)
AU (1) AU2022405026A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240392A1 (cg-RX-API-DMAC7.html)
IL (1) IL313404A (cg-RX-API-DMAC7.html)
MX (1) MX2024007070A (cg-RX-API-DMAC7.html)
WO (1) WO2023107658A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.

Also Published As

Publication number Publication date
EP4444286A1 (en) 2024-10-16
JP2024542844A (ja) 2024-11-15
AU2022405026A1 (en) 2024-06-20
IL313404A (en) 2024-08-01
WO2023107658A1 (en) 2023-06-15
US20250041248A1 (en) 2025-02-06
MX2024007070A (es) 2024-08-22
CN118678950A (zh) 2024-09-20
CA3240392A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
Racke et al. Pain in multiple sclerosis: understanding pathophysiology, diagnosis, and management through clinical vignettes
US20250302734A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
Graziano et al. Dose-response study of oral 2, 3-dimercaptosuccinic acid in children with elevated blood lead concentrations
JP6895949B2 (ja) フェンフルラミンを用いたレノックス・ガストー症候群の処置方法
Papp et al. Toxic effects of iproniazid in a patient with angina
KR20190142364A (ko) 펜플루라민을 사용하여 두즈 증후군을 치료하는 방법
US20200113883A1 (en) Durable treatment with 4-aminopyridine in patients with demyelination
RU2563821C2 (ru) Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы
JP2015522077A (ja) ラキニモドおよびファムプリジンの組合せによる多発性硬化症の治療
Perry et al. Clinical study of mianserin, imipramine and placebo in depression: blood level and MHPG correlations.
Doshay et al. Artane® therapy for parkinsonism: A preliminary study of results in one hundred and seventeen cases
Mishra et al. Intravesical tacrolimus in treatment of intractable interstitial cystitis/bladder pain syndrome–A pilot study
Hollander et al. Pharmacologic approaches in the treatment of pathological gambling
González-Vílchez et al. Conversion from immediate-release tacrolimus to prolonged-release tacrolimus in stable heart transplant patients: a retrospective study
US20250041248A1 (en) Alz-801 for use in treating alzheimer's disease
JUDAH et al. Psychiatric response of geriatric-psychiatric patients to Mellaril (TP-21 Sandoz)
TW202440106A (zh) 用於治療勃起障礙之化合物
KR960006068B1 (ko) 이미다벤조디아제핀을 함유하는 공포상태의 예방 및 중지용 약제
Kabeš et al. Biological correlates of piracetam clinical effects in psychotic patients
CHECK et al. 2.72 Atomoxetine
WO2009051922A1 (en) Methods of treating alzheimer's disease with (+) - isopropyl 2-methoxyethyl 4-(2-chloro-3- cyano-phenyl) -1, 4-dihydro-2, 6-dimethyl-pyridine-3, 5-dicarboxylate and a cholinesterase inhibitor
RU2026100606A (ru) Солриамфетол для лечения некоторых неврологических заболеваний
HK40083190A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
Raval et al. Drug information of Aducanumab and its effectiveness for Alzheimer’s disease: A clinical review

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000